BLINCYTO 35/38.5 mcg
- Name: BLINCYTO
- Generic Name: Blinatumomab
- Strength: 35 mcg | 38.5 Single-Dose Vial
- Manufactured : Amgen Inc
Blincyto contains Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. Blincyto uses are:
- B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal 0.1%.
- Relapsed or refractory B-cell precursor ALL (Acute Lymphoblastic Leukemia).
Note: – Blincyto is an FDA approved drug.
- Assess patients with blinatumomab injection for signs and symptoms of neurological toxicities. Advise outpatients on Blinatumomab to contact their health specialist if they develop signs/symptoms of neurological toxicities.
- Monitor patients with Blincyto doses for signs and symptoms of infection and treat appropriately.
- Assess laboratory parameters (including, but not limited to, WBC count and absolute neutrophil count) during blinatumomab infusion. Interrupt this medication if prolonged neutropenia occurs.
- Monitor aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and total blood bilirubin before the start of and while on Blincyto 35 mcg treatment.
- Assess patients who develop signs of pancreatitis. Management of pancreatitis may need either temporary interruption or discontinuation of Blincyto injection and dexamethasone.
- Healthcare professionals recommend not to have vaccination with live virus vaccines for at least before 2 weeks Blinatumomab 35 mcg treatment, during treatment, and until immune recovery following the last cycle of Blinatumomab.
How to get Blincyto (Blinatumomab) in India?
BLINCYTO can be imported by patients or government hospitals in the patients’ name only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by the government of India)
How does the order confirm?
The order will be confirmed only after the receipt of:
- A valid prescription by healthcare professionals
- Import permit if applicable
Is BLINCYTO available in India?
BLINCYTO is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability in India.
- Medicine Price.
- Finding Genuine and reliable sources from Canada, Europe, the USA and Australia
- Ensuring 100% transparency.
BLINCYTO can be made available to patients, doctors and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after receiving a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of BLINCYTO (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for blinatumomab price in India.
We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network can source the BLINCYTO (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network can dispense any valid prescription in the short span of time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
Indian Pharma Network helps you to connect with potential distributors, wholesalers, suppliers and dealers of Blincyto in India.
What kind of drug is Blincyto?
Blincyto is a prescription only medicine, which is used in treating patients with B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal 0.1% and relapsed or refractory B-cell precursor ALL (Acute Lymphoblastic Leukemia).
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.